Shares of Perrigo Company plc (NYSE:PRGO – Get Free Report) have been given a consensus rating of “Reduce” by the seven ratings firms that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $22.50.
PRGO has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $20.00 target price (down previously from $32.00) on shares of Perrigo in a research note on Thursday, November 6th. Jefferies Financial Group reduced their price target on shares of Perrigo from $27.00 to $23.00 and set a “hold” rating on the stock in a research note on Monday, October 27th. Wall Street Zen lowered shares of Perrigo from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Canaccord Genuity Group dropped their target price on shares of Perrigo from $40.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, November 6th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Perrigo in a research report on Tuesday.
Get Our Latest Research Report on Perrigo
Insiders Place Their Bets
Hedge Funds Weigh In On Perrigo
Institutional investors have recently bought and sold shares of the business. Danske Bank A S bought a new position in Perrigo in the third quarter worth approximately $53,000. Sherbrooke Park Advisers LLC purchased a new position in shares of Perrigo in the 3rd quarter valued at $286,000. Lombard Odier Asset Management USA Corp raised its position in shares of Perrigo by 25.7% in the 3rd quarter. Lombard Odier Asset Management USA Corp now owns 98,106 shares of the company’s stock worth $2,185,000 after acquiring an additional 20,040 shares in the last quarter. Lighthouse Investment Partners LLC purchased a new stake in shares of Perrigo during the 3rd quarter worth $1,782,000. Finally, Crawford Investment Counsel Inc. boosted its position in Perrigo by 3.2% during the third quarter. Crawford Investment Counsel Inc. now owns 1,274,467 shares of the company’s stock valued at $28,382,000 after purchasing an additional 39,236 shares in the last quarter. 95.91% of the stock is owned by hedge funds and other institutional investors.
Perrigo Stock Down 0.5%
Shares of NYSE PRGO opened at $13.35 on Friday. Perrigo has a 1 year low of $12.17 and a 1 year high of $30.93. The firm has a 50-day simple moving average of $18.66 and a two-hundred day simple moving average of $23.14. The company has a market cap of $1.84 billion, a P/E ratio of -23.02 and a beta of 0.42. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.32 and a quick ratio of 1.24.
Perrigo (NYSE:PRGO – Get Free Report) last released its earnings results on Wednesday, November 5th. The company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.05. Perrigo had a positive return on equity of 9.09% and a negative net margin of 1.86%.The firm had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1.10 billion. During the same quarter in the prior year, the firm posted $0.81 earnings per share. The company’s quarterly revenue was down 4.1% on a year-over-year basis. Perrigo has set its FY 2025 guidance at 2.700-2.80 EPS. Research analysts anticipate that Perrigo will post 2.56 earnings per share for the current year.
Perrigo Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 16th. Shareholders of record on Friday, November 28th will be issued a $0.29 dividend. This represents a $1.16 annualized dividend and a dividend yield of 8.7%. The ex-dividend date is Friday, November 28th. Perrigo’s dividend payout ratio is currently -305.26%.
About Perrigo
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Read More
- Five stocks we like better than Perrigo
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Power On: Applied Digital’s First AI Data Center Goes Live
- How to Invest in the FAANG Stocks
- Alphabet: The AI Leader Best Positioned to Dominate 2026
- Best Energy Stocks – Energy Stocks to Buy Now
- 2 Reasons to Load Up on Fiserv, 1 to Stay Away
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.
